Instil Bio Inc. (TIL) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Instil Bio Inc. (TIL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

20.11

1.09 (5.73%)

At close: Jan 14, 2025, 3:59 PM

20.04

-0.35%

After-hours Jan 14, 2025, 04:05 PM EST

undefined% (undefined)

Bid	19.35
Market Cap	131.24M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-11.56
PE Ratio (ttm)	-1.74
Forward PE	n/a
Analyst	Buy

Ask	21.3
Volume	88,738
Avg. Volume (20D)	125,426
Open	19.64
Previous Close	19.02
Day's Range	19.47 - 21.19
52-Week Range	7.35 - 92.00
Beta	undefined

About TIL

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize f...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 19, 2021

Employees 49

Stock Exchange NASDAQ

Ticker Symbol TIL

Website https://instilbio.com

Analyst Forecast

According to 4 analyst ratings, the average rating for TIL stock is "Buy." The 12-month stock price forecast is $110, which is an increase of 446.99% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 week ago · Source

+14.84%

Instil Bio shares are trading higher after Jefferi... Unlock content with Pro Subscription

2 months ago · Source

-5.51%

Instil Bio shares are trading higher after the company reported better-than-expected Q2 EPS results.

News

1 week ago · benzinga.com

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

Jefferies upgraded Instil Bio TIL, noting that 2024 was a banner year for the PD-(L)1xVEGF class.

1 month ago · seekingalpha.com

Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity

Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. SYN-2510 targets the promising PD-L1/VEGF oncology pathway. The company recently licensed assets from ImmuneOnco Biopharm...